International Journal of Medical and Pharmaceutical Research
2024, Volume-5, Issue-6 doi: 10.5281/zenodo.12787872
Original Research Article
Comparative Evaluation of Diffusion Weighted Imaging and Magnetic Resonance Spectroscopy in the Diagnosis and Grading of Brain Tumors: A Prospective Clinical Study
Published
Dec. 11, 2024
Abstract

Background: Accurate diagnosis and grading of brain tumors are critical for effective treatment. This study evaluated the diagnostic accuracy of Diffusion Weighted Imaging (DWI) and Magnetic Resonance Spectroscopy (MRS) compared to conventional MRI, with histopathology as the gold standard.Methods: This prospective study included 60 patients undergoing MRI for suspected brain tumors. Each patient was assessed using conventional MRI, DWI, and MRS. Apparent Diffusion Coefficient (ADC) values and metabolic ratios were analyzed, and diagnostic performance was compared to histopathological results. Statistical analysis was performed using SPSS, with p-values < 0.05 considered significant. Results:Glioblastomamultiforme was the most common tumor, comprising 26.7% of cases. MRS demonstrated a diagnostic accuracy of 82.5%, outperforming DWI (72.5%). MRS had a sensitivity of 75% and specificity of 90.9% for glioblastomamultiforme, while DWI had a sensitivity of 68.75% and specificity of 86.36%. The mean ADC values for high-grade gliomas (0.65 ± 0.13 × 10⁻³ mm²/s) were significantly lower than for low-grade gliomas (1.02 ± 0.16 × 10⁻³ mm²/s; p < 0.001).Conclusion: MRS is a reliable tool for non-invasive brain tumor grading, showing higher diagnostic accuracy than DWI. Combining DWI and MRS with conventional MRI could enhance diagnostic precision, guiding better treatment planning. Future research should explore integrated imaging approaches for improved tumor diagnosis and monitoring.

Recommended Articles
Loading Image...
Volume-5, Issue-6
Citations
1919 Views
283 Downloads
Share this article
License
Copyright (c) International Journal of Medical and Pharmaceutical Research
pdf Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.
IJMPR open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.
Logo
International Journal of Medical and Pharmaceutical Research
About Us
The International Journal of Medical and Pharmaceutical Research (IJMPR) is an EMBASE (Elsevier)–indexed, open-access journal for high-quality medical, pharmaceutical, and clinical research.
Follow Us
© Copyright IJMPR | All Rights Reserved